Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 44

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 44
---
Q:

What happens if I vote against the Business Combination Proposal?

A:

If the Business Combination Proposal is not approved and we do not otherwise consummate an

<div align='center'>xvi</div>

TABLE OF CONTENTS

alternative business combination or amend the Iris Certificate of Incorporation by stockholder approval by March 31, 2025 (subject to an additional three month extension at the discretion of the Iris Board), we will be required to dissolve and liquidate our Trust Account by returning the then remaining funds in such account to the public stockholders. For additional information, see the section entitled “Information About Iris — Liquidation if No Business Combination ” for more information.

**Q:**

#### Do I have redemption rights?
A:

Pursuant to our charter and the Trust Agreement, eligible holders of Iris Class A Shares may elect to have their shares redeemed for cash at a redemption price per share calculated in accordance with our charter, by tendering the Iris Class A Shares of such holder for redemption not later than 5:00 p.m. Eastern Time on the date that is two Business Days prior to the date of the Special Meeting. As of January 2, 2025, this would have amounted to approximately $11.47 per share (net of all applicable taxes payable from the Trust Account). If a holder of public shares properly exercises his, her or its redemption rights, then such holder will be exchanging his, her or its shares of Iris Class A Common Stock for cash and will no longer own such shares. See the section entitled “ Special Meeting of Iris Stockholders — Redemption Rights and Procedures ” for procedures to be followed if you wish to redeem your shares for cash and not own the ParentCo common stock following consummation of the Business Combination.

After the special meeting held by Iris on December 20, 2024, to vote upon a charter amendment to extend the time to complete a business combination until March 31, 2025 (subject to an additional three month extension at the discretion of the Iris Board), public stockholders elected to redeem 64,453 shares of common stock, resulting in $2,001,033 of funds remaining in the Trust Account (as adjusted for redemptions paid out of the Trust Account in January 2025 and subject to adjustment for such further taxes as may be payable from the Trust Account) and 174,477 shares of Iris common stock held by the public stockholders.

Notwithstanding the foregoing, a holder of public shares, together with any of its affiliates